HealthDay on MSN20h
FDA Approves Spravato Nasal Spray for Treatment-Resistant DepressionThe U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback